Search

everythinglearnresearchcommunity

for

Search:↓

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.

The treatment was effective for advanced non-Hodgkin's lymphomas.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

The treatment is safe and shows promise for metastatic breast cancer.

A patient with lupus experienced complete hair regrowth after treatment with thalidomide.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.